 |
|
Tissue Engineering in the Genitourinary System
M. J. Friedrich
JAMA. 2000;283:2509.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Boston—Evolving from dream to reality in only a few years, tissue engineering is beginning to provide clinical options in urology. This is quite an accomplishment, said Anthony Atala, MD, of Harvard Medical School, given that 10 years ago keeping urothelial cells alive in the laboratory for more than a few weeks was difficult.
Atala, who spoke at the American Society of Andrology meeting last month, has contributed much to the success of the field. It was at Harvard under his direction that the first urologic application of cell-based tissue engineering—the injection of autologous cells for the correction of vesicoureteral reflux in children—took place.
In this treatment, investigators inject a bulking agent under the ureteral orifice that changes the angle of the ureter and narrows the lumen, thereby preventing retrograde urine flow into the kidney, Atala explained. The injected material, which consists of chondrocytes grown from a . . . [Full Text of this Article]
|
